We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Avidity Tests Discriminate Between Acute and Past Infections

By LabMedica International staff writers
Posted on 27 Aug 2012
Avidity assays discriminate between acute and past infections by determining the avidity of specific Immunoglobulin G (IgG) antibodies. More...
This is particularly important in pregnancy diagnostics, where an acute infection may pose a risk to the fetus.

The Euroimmun AG (Luebeck, Germany) avidity portfolio includes enzyme-linked immunosorbent assays (ELISA) and indirect immunofluorescence tests (IIFT) and comprises infections caused by the following organisms: Toxoplasma gondii, Rubellavirus, Epstein-Barr virus, West Nile virus, Cytomegalovirus, varicella zoster virus, measles virus, and Tick-borneencephalitisvirus (TBE).

On first contact with an infectious agent, the immune system cannot induce matching antibodies. But over time the B-lymphocytes adapt to the pathogen and the avidity of the specific IgG increases by several powers. Thus, the detection of high-avidity antibodies is a reliable indication that an infection took place some time ago, whereas low-avidity antibodies indicate an acute infection.

All assays incorporate an incubation step with a urea solution, which destroys the weak bonds between low-avidity antibodies and the antigenic target, while leaving the stable bonds formed by high-avidity antibodies intact. Bound antibodies are then detected according to the usual ELISA or IIFT procedure.

The investigation of IgM antibodies is traditionally used to identify acute infections, but it has several limitations: IgM may be only transient or may not be reliably detected in an acute infection, or IgM may persist for months or years after recovery, making interpretation difficult. In these instances, avidity testing can clarify the diagnosis without the need to take a second sample from the patient.

Related Links:

Euroimmun AG




Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Blood Glucose Reference Analyzer
Nova Primary
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.